4.7 Review

G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases

Journal

FRONTIERS IN PHARMACOLOGY
Volume 10, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2019.00112

Keywords

GRK2; GPCR; cardiovascular; obesity; NAFLD; insulin resistance; inhibitors

Funding

  1. Ministerio de Economia
  2. Industria y Competitividad (MINECO) of Spain [SAF2017-84125-R, SAF2016-80305-P]
  3. CIBERCV-Instituto de Salud Carlos III, Spain [CB16/11/00278, CB16/11/00286]
  4. European FEDER
  5. Programa de Actividades en Biomedicina de la Comunidad de Madrid [B2017/BMD-3671-INFLAMUNE, B2017/BMD-3676-AORTASANA]

Ask authors/readers for more resources

G protein-coupled receptor kinase 2 (GRK2) is a central signaling node involved in the modulation of many G protein-coupled receptors (GPCRs) and also displaying regulatory functions in other cell signaling routes. GRK2 levels and activity have been reported to be enhanced in patients or in preclinical models of several relevant pathological situations, such as heart failure, cardiac hypertrophy, hypertension, obesity and insulin resistance conditions, or non-alcoholic fatty liver disease (NAFLD), and to contribute to disease progression by a variety of mechanisms related to its multifunctional roles. Therefore, targeting GRK2 by different strategies emerges as a potentially relevant approach to treat cardiovascular disease, obesity, type 2 diabetes, or NAFLD, pathological conditions which are frequently interconnected and present as co-morbidities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available